As of November 6, 2026, Serina Therapeutics, Inc. is a publicly traded company (NYSE: SER). The largest holder reporting an active stake on Schedule 13D is Juvenescence Limited, at 27.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Sio Capital Management, LLC (7.87%) (Schedule 13D/A, July 22, 2026).
Is this your company?
About to sign with, pay or invest in Serina Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Serina Therapeutics, Inc. a real, registered company?
- Serina Therapeutics, Inc. files with the SEC under CIK 1708599 (its SEC filings).
- Its shares are listed under the ticker SER on NYSE (SEC company record).
- Incorporated in Alabama; business address in Huntsville, Alabama, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SERINA THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Srini Tenjarla, Chief Technology Officer (Form 8-K filed 2026-04-21). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sio Capital Management, LLC (filed 2026-11-03).
Who are Serina Therapeutics, Inc.'s owners and officers?
Serina Therapeutics, Inc.: incorporated in Alabama; business address in Huntsville, Alabama; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-03 | Sio Capital Management, LLC | 7.87% |
| Schedule 13D/A, 2026-07-22 | Juvenescence Limited | 27.3% |
| Schedule 13G, 2026-05-04 | Sio Capital Management, LLC | 6.71% |
Questions about who owns Serina Therapeutics, Inc.
Who owns Serina Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Serina Therapeutics, Inc.: Juvenescence Limited (27.3%, Schedule 13D/A, filed 2026-07-22) and Sio Capital Management, LLC (7.87%, Schedule 13G/A, filed 2026-11-03).
Who are the largest shareholders of Serina Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Serina Therapeutics, Inc. on this page are Juvenescence Limited (27.3%) and Sio Capital Management, LLC (7.87%).
When did Juvenescence Limited buy into Serina Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Juvenescence Limited on this page is the Schedule 13D/A, filed 2026-07-22, reporting 27.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Serina Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Serina Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Serina Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-21 | Srini Tenjarla | Chief Technology Officer | appointed |
Which insiders own Serina Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 8,564,382 shares (33.7% of shares outstanding) (Form 4, 2026-06-22).
- Juvenescence Ltd, a 10% owner: 6,034,376 shares (23.8% of shares outstanding), held indirectly through a juv uk (Form 4, 2025-02-03).
- , a director: 232,294 shares (0.91% of shares outstanding), 589 held directly and 231,705 indirectly (Form 4, 2026-06-22).
- , a director: 30,100 shares (0.12% of shares outstanding) (Form 4, 2026-06-22).
- , a director: 12,183 shares (0.05% of shares outstanding) (Form 4, 2026-05-22).
Shares outstanding: 25,400,473 as of 2026-08-10, from the company's latest SEC cover page.
How much has Serina Therapeutics, Inc. raised?
Latest IPO step: Serina Therapeutics, Inc. filed to go public (S-1, 2026-08-24).
IPO filings: S-1, 2026-08-24, S-1/A, 2024-07-03; ticker SER on NYSE American.
Keep reading
More on Serina Therapeutics, Inc. and the records around it.
Serina Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/serina-therapeutics